Orlov V A, Sokolova V I, Sarsenbaeva D I, Manuĭlov K K
Antibiot Khimioter. 1994 Feb-Mar;39(2-3):45-8.
Antibiotic susceptibility of 279 strains of gram-positive and gram-negative isolates from patients with bronchopulmonary infections was tested. It was shown that the frequency of resistance to ampicillin and sulacillin amounted to 36.5 and 28.8 per cent respectively. The highest clinical efficacy of sulacillin was observed in the treatment of acute pneumonia (good and satisfactory results in 76.2 and 19 per cent of the cases respectively) and chronic nonobstructive bronchitis (good and satisfactory results in 80 and 16 per cent respectively). The clinical efficacy of sulacillin was somewhat lower in the treatment of chronic obstructive bronchitis (good and satisfactory results in 50 and 30 per cent of the cases respectively). In the treatment of chronic purulent bronchitis no clinical effect was detected in 30 per cent of the cases and in 70 per cent of the cases the results were satisfactory. The total frequency of adverse reactions to sulacillin amounted to 18.8 per cent.
对279株来自支气管肺部感染患者的革兰氏阳性和阴性分离菌株进行了抗生素敏感性测试。结果表明,对氨苄西林和舒巴坦的耐药率分别为36.5%和28.8%。舒巴坦治疗急性肺炎的临床疗效最高(分别有76.2%和19%的病例效果良好和令人满意)以及慢性非阻塞性支气管炎(分别有80%和16%的病例效果良好和令人满意)。舒巴坦治疗慢性阻塞性支气管炎的临床疗效略低(分别有50%和30%的病例效果良好和令人满意)。在治疗慢性化脓性支气管炎时,30%的病例未检测到临床效果,70%的病例结果令人满意。舒巴坦不良反应的总发生率为18.8%。